We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00159640
First Posted: September 12, 2005
Last Update Posted: March 28, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Pfizer
  Purpose
The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.

Condition Intervention Phase
Pain Drug: PD-217,014 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double Blind, Dose-Response, Placebo And Gabapentin Controlled Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • To characterise the effectiveness of PD-217,014 in the treatment of chronic pain. A numerical pain intensity rating scale is used to assess pain and a mean endpoint (week 4) pain score change from baseline is calculated.

Secondary Outcome Measures:
  • - Assess the effect of PD-217,014 on responder rate based on the primary endpoint, mean endpoint sleep interference score and the SF-McGill questionnaire (change from baseline to week 4)

Estimated Enrollment: 315
Study Start Date: February 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have pain present for more than 3 months after the healing of shingles skin rash.
  • Patients at screening must have a score >=40 mm on the pain visual analogue scale.

Exclusion Criteria:

  • Patients with poor renal function.
  • Patients with other severe pain, that may impair the self-assessment of the pain due to shingles.
  • Patients with abnormal electrocardiogram.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159640


  Hide Study Locations
Locations
Australia, New South Wales
Pfizer Investigational Site
Warrawong, New South Wales, Australia
Pfizer Investigational Site
Westmead, New South Wales, Australia
Australia, Queensland
Pfizer Investigational Site
Kippa Ring, Queensland, Australia
Pfizer Investigational Site
Maroochydore, Queensland, Australia
Australia, South Australia
Pfizer Investigational Site
Bedford Park, South Australia, Australia
Australia, Western Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Australia
Pfizer Investigational Site
Woodville, Australia
Canada, British Columbia
Pfizer Investigational Site
Kelowna, British Columbia, Canada
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Pfizer Investigational Site
Toronto, Ontario, Canada
Canada, Quebec
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
Ste-foy, Quebec, Canada
Czech Republic
Pfizer Investigational Site
Brno, Czech Republic
Pfizer Investigational Site
Ceske Budejovice, Czech Republic
Pfizer Investigational Site
CZ-Praha 8, Czech Republic
Pfizer Investigational Site
Plzen, Czech Republic
Pfizer Investigational Site
Praha 5, Czech Republic
Netherlands
Pfizer Investigational Site
Arnhem, Netherlands
Pfizer Investigational Site
Breda, Netherlands
Pfizer Investigational Site
Kampen, Netherlands
Pfizer Investigational Site
Roosendaal, Netherlands
Pfizer Investigational Site
Rotterdam, Netherlands
Pfizer Investigational Site
Stadskanaal, Netherlands
Spain
Pfizer Investigational Site
Barcelona, Spain
Pfizer Investigational Site
Granada, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Malaga, Spain
Pfizer Investigational Site
Sevilla, Spain
United Kingdom
Pfizer Investigational Site
Portsmouth, Hants, United Kingdom
Pfizer Investigational Site
Northampton, Northants, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00159640     History of Changes
Other Study ID Numbers: A4451006
First Submitted: September 7, 2005
First Posted: September 12, 2005
Last Update Posted: March 28, 2007
Last Verified: March 2007

Additional relevant MeSH terms:
Neuralgia
Neuralgia, Postherpetic
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms